Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,097 questions · 3,266 findings · 631 reviews

No studies found 430 · 13.2%GRADE not reported 193 · 5.9%Very low 995 · 30.5%Low 904 · 27.7%Moderate 591 · 18.1%High 153 · 4.7%

Intervention diet vs usual on‐treatment diet

QoL · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Diet interventions showed no clear difference in QOL scores (IBDQ) (higher scores better) compared with usual on‐treatment diet (low certainty).

1 finding from 1 review

Intervention diet vs usual on‐treatment diet

Mean GI symptom scores (Vaizey scale) (higher scores better) · People undergoing pelvic radiotherapy for urological, gynaecological or colorectal cancer

Summary of findings: Diet interventions showed no clear difference in mean GI symptom scores (Vaizey scale) (higher scores better) compared with usual on‐treatment diet (low certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review

LABA/ICS vs LAMA

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

LABA/ICS vs LAMA

Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).

1 finding from 1 review

LABA/ICS vs LABA

Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS leads to lower moderate to severe exacerbations: high‐risk population compared with LABA (high certainty).

1 finding from 1 review

LABA/ICS vs LABA

Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LABA (moderate certainty).

1 finding from 1 review

LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)

Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%

LABA/LAMA showed no clear difference in severe exacerbations: high‐risk population compared with LABA/ICS (moderate certainty).

1 finding from 1 review